Floatz Rating
CC47/100
Confidence
Indicative
Sponsor
Arrowhead Pharmaceuticals
Modality
nucleic_acid
Development Phase
Phase 1
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
32Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03783377CT.gov Study of ARO-APOC3 in Healthy Volunteers, Hypertriglyceridemic Patients and Patients With Familial Chylomicronemia Syndrome (FCS) | — | Completed | — | — | — |
NCT06796426CT.gov Treatment Protocol of Plozasiran in Adults With High-Risk Severe Hypertriglyceridemia (SHTG) and in Adults and Adolescents With FCS | — | Available | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Indicative
Detailed axis rationale is planned and will be published soon.
Same indication · Hypertriglyceridemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Plozasiran (this asset) | Arrowhead Pharmaceuticals | P1 | CC · 47 |
| Fenofibrate | Abbott | P4 | BB |
| (3S)-TETRAHYDRO-3-FURYL ((.ALPHA.S)-.ALPHA.-((1R)-1-HYDROXY-2-(N1-ISOBUTYLSULFANILAMIDO)ETHYL)PHENETHYL)CARBAMATE PHOSPHATE (ESTER) | Felizarta, Franco, M.D. | P4 | BB |
| Saffron | Birjand University of Medical Sciences | P4 | BB |
| Atorvastatin | The University of Western Australia | P4 | BB |
| NORVIR | Felizarta, Franco, M.D. | P4 | BB |
| Simvastatin | Koval' O., MD | P4 | BB |
| Raltegravir | The Miriam Hospital | P3 | BB |
| Niacin | University of South Dakota | P4 | B |
+19 more in the Hypertriglyceridemia cohort
Other indications for Plozasiran
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Familial Chylomicronemia Syndrome | — | P3 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- FenofibrateAbbottBB
- (3S)-TETRAHYDRO-3-FURYL ((.ALPHA.S)-.ALPHA.-((1R)-1-HYDROXY-2-(N1-ISOBUTYLSULFANILAMIDO)ETHYL)PHENETHYL)CARBAMATE PHOSPHATE (ESTER)Felizarta, Franco, M.D.BB
- SaffronBirjand University of Medical SciencesBB
- AtorvastatinThe University of Western AustraliaBB
- NORVIRFelizarta, Franco, M.D.BB
Citation
Floatz Terminal. Plozasiran in Hypertriglyceridemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/plozasiran-hypertriglyceridemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →